Found: 2
Select item for more details and to access through your institution.
Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.
- Published in:
- Journal of Diabetes Investigation, 2019, v. 10, n. 4, p. 1012, doi. 10.1111/jdi.12985
- By:
- Publication type:
- Article
1192-P: Dapagliflozin Reduces Intrahepatic Triglyceride Content in Japanese Patients with Type 2 Diabetes Treated with Oral Antidiabetic Agents: A Randomized, Clinical Trial.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1192-P
- By:
- Publication type:
- Article